MX421375B - Terapia genica cardiaca con aav para cardiomiopatia - Google Patents

Terapia genica cardiaca con aav para cardiomiopatia

Info

Publication number
MX421375B
MX421375B MX2020013313A MX2020013313A MX421375B MX 421375 B MX421375 B MX 421375B MX 2020013313 A MX2020013313 A MX 2020013313A MX 2020013313 A MX2020013313 A MX 2020013313A MX 421375 B MX421375 B MX 421375B
Authority
MX
Mexico
Prior art keywords
aav
cardiomyopathy
gene therapy
cardiac gene
transgenes
Prior art date
Application number
MX2020013313A
Other languages
English (en)
Other versions
MX2020013313A (es
Inventor
Hugh Lee Sweeney
Margaret Mary Sleeper
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2020013313A publication Critical patent/MX2020013313A/es
Publication of MX421375B publication Critical patent/MX421375B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a composiciones y métodos útiles para tratar afecciones cardíacas; las composiciones y métodos divulgados se basan en una terapia con AAV que comprende un vector de AAV recombinante para administrar dos o más transgenes al corazón de un sujeto, en donde los transgenes comprenden una proteína de la familia S100 y un inhibidor apoptótico; en algunos aspectos, el direccionamiento hacia múltiples fuentes de una o más afecciones cardíacas puede proporcionar beneficios sinérgicos durante el tratamiento.
MX2020013313A 2018-06-08 2019-06-07 Terapia genica cardiaca con aav para cardiomiopatia MX421375B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682772P 2018-06-08 2018-06-08
US201962822015P 2019-03-21 2019-03-21
PCT/US2019/036157 WO2019237067A1 (en) 2018-06-08 2019-06-07 Aav cardiac gene therapy for cardiomyopathy

Publications (2)

Publication Number Publication Date
MX2020013313A MX2020013313A (es) 2021-02-22
MX421375B true MX421375B (es) 2025-03-14

Family

ID=68770676

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013313A MX421375B (es) 2018-06-08 2019-06-07 Terapia genica cardiaca con aav para cardiomiopatia

Country Status (14)

Country Link
US (1) US20210260215A1 (es)
EP (1) EP3814512A4 (es)
JP (2) JP2021526818A (es)
KR (1) KR20210018902A (es)
CN (1) CN112272705A (es)
AU (1) AU2019282822B2 (es)
BR (1) BR112020024935A2 (es)
CA (1) CA3100280A1 (es)
CL (1) CL2020003190A1 (es)
CO (1) CO2020016718A2 (es)
IL (1) IL279225B2 (es)
MX (1) MX421375B (es)
SG (1) SG11202011061SA (es)
WO (1) WO2019237067A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021016126A1 (en) * 2019-07-19 2021-01-28 University Of Florida Researchfoundation, Incorporated Aav cardiac gene therapy for cardiomyopathy in humans
WO2022031756A1 (en) * 2020-08-05 2022-02-10 Spacecraft Seven, Llc Csrp3 (cysteine and glycine rich protein 3) gene therapy
JP2024501957A (ja) * 2020-12-23 2024-01-17 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 心臓遺伝子治療のためのベクターの増大したパッケージング効率
IL314963A (en) * 2022-03-02 2024-10-01 Cevec Pharmaceuticals Gmbh Improved cell lines and methods for the production of adeno-associated vectors
EP4239063A1 (en) * 2022-03-02 2023-09-06 CEVEC Pharmaceuticals GmbH Improved cell lines and methods for the production of adeno-associated vectors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
CA2914029A1 (en) * 2013-06-07 2014-12-11 The Regents Of The University Of California Cycle adenosine monophosphate-incompetent adenylyl cyclase and compositions and methods for treating heart failure and increasing cardiac function
PL3405215T3 (pl) * 2016-01-19 2022-10-31 The Regents Of The University Of California Sposoby leczenia choroby danona i innych zaburzeń autofagii
US20170348387A1 (en) * 2016-02-29 2017-12-07 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for nphp5 lca-ciliopathy

Also Published As

Publication number Publication date
WO2019237067A1 (en) 2019-12-12
CO2020016718A2 (es) 2021-04-08
AU2019282822A1 (en) 2020-11-26
SG11202011061SA (en) 2020-12-30
IL279225B1 (en) 2024-07-01
BR112020024935A2 (pt) 2021-03-09
US20210260215A1 (en) 2021-08-26
CL2020003190A1 (es) 2021-04-30
CA3100280A1 (en) 2019-12-12
CN112272705A (zh) 2021-01-26
IL279225A (en) 2021-01-31
EP3814512A4 (en) 2022-03-09
KR20210018902A (ko) 2021-02-18
MX2020013313A (es) 2021-02-22
IL279225B2 (en) 2024-11-01
AU2019282822B2 (en) 2025-09-04
JP2024097779A (ja) 2024-07-19
JP2021526818A (ja) 2021-10-11
EP3814512A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
CO2020016718A2 (es) Terapia génica cardíaca con aav para cardiomiopatía
CO2022001686A2 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos
MX2022003063A (es) Composiciones terapeuticas, combinaciones y metodos de uso.
UY38999A (es) Degradadores de proteína tirosina fosfatasa y métodos de uso de los mismos
MX2020011786A (es) Oligomeros antisentido para tratamiento de afecciones y enfermedades.
BR112022002905A2 (pt) Composições e métodos para modular splicing e expressão de proteína
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
CL2022003147A1 (es) Composiciones y métodos para tratar pérdida auditiva asociada con gjb2
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
CO2021004934A2 (es) Composiciones y métodos para tratar retinitis pigmentosa
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112022009279A2 (pt) Tratamento de angioedema hereditário com vetores de terapia gênica específicos do fígado
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
BR112022002794A2 (pt) Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1
CO2023007325A2 (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
MX2022000232A (es) Composiciones y metodos para tratar o evitar infecciones oculares con filociclovir.
EA202092654A1 (ru) Генная терапия сердца с помощью aav при кардиомиопатии
ZA202102023B (en) Potentiation of helminth treatment
CL2023001731A1 (es) Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca.
MX2022000349A (es) Cardioterápico.
MX2023008501A (es) Composiciones y metodos para remodelar el cuerpo y procedimientos quirurgicos.
BR112022020846A2 (pt) Agentes imunoestimuladores em combinação com inibidores de angiogênese
MX2021014028A (es) Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
AR120249A1 (es) Vectores virales adeno-asociados para el tratamiento de la enfermedad de niemann-pick tipo c
EA202090584A1 (ru) Антисмысловые олигомеры для лечения состояний и заболеваний